Title : Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.

Pub. Date : 2022 Apr

PMID : 35092538






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSION: Our analyses suggest that 14% of ER+/Her2- patients may be HRD and therefore potentially eligible for treatments with HRD-directed therapies such as platinum agents and PARP inhibitors. Platinum erb-b2 receptor tyrosine kinase 2 Homo sapiens